Blar i NTNU Open på forfatter "Windisch, Marc P."

Viser treff 1-4 av 4

    • Common nodes of virus–host interaction revealed through an integrated network analysis 

      Bösl, Korbinian; Ianevski, Aleksandr; Than, Thoa T.; Andersen, Petter I.; Kuivanen, Suvi; Teppor, Mona; Zusinaite, Eva; Dumpis, Uga; Vitkauskiene, Astra; Cox, Rebecca Jane; Kallio-Kokko, Hannimari; Bergqvist, Anders; Tenson, Tanel; Merits, Andres; Oksenych, Valentyn; Bjørås, Magnar; Anthonsen, Marit Walbye; Shum, David H.K.; Kaarbø, Mari; Vapalahti, Olli; Windisch, Marc P.; Superti-Furga, Giulio; Snijder, Berend; Kainov, Denis; Kandasamy, Richard Kumaran (Journal article; Peer reviewed, 2019)
      Viruses are one of the major causes of acute and chronic infectious diseases and thus a major contributor to the global burden of disease. Several studies have shown how viruses have evolved to hijack basic cellular pathways ...

    • Mono- and combinational drug therapies for global viral pandemic preparedness 

      Ianevski, Aleksandr; Yao, Rouan; Simonsen, Ronja Meyer; Myhre, Vegard; Ravlo, Erlend; Kaynova, Gerda D.; Zusinaite, Eva; White, Judith M.; Polyak, Stephen J.; Oksenych, Valentyn; Windisch, Marc P.; Pan, Qiuwei; Lastauskienė, Eglė; Vitkauskienė, Astra; Matukevičius, Algimantas; Tenson, Tanel; Bjørås, Magnar; Kainov, Denis (Peer reviewed; Journal article, 2022)
      Broadly effective antiviral therapies must be developed to be ready for clinical trials, which should begin soon after the emergence of new life-threatening viruses. Here, we pave the way towards this goal by reviewing ...

    • Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19 

      Meehyun, Ko; Chang, Soo Young; Byun, Soo Young; Ianevski, Aleksandr; Choi, Inhee; Pham Hung, Anne-Laure; Ravlo, Erlend; Wang, Wei; Bjørås, Magnar; Kainov, Denis; Shum, David; Min, Ji-Young; Windisch, Marc P. (Peer reviewed; Journal article, 2021)
      Therapeutic options for coronaviruses remain limited. To address this unmet medical need, we screened 5406 compounds, including United States Food and Drug Administration (FDA)-approved drugs and bioactives, for activity ...

    • Synergistic interferon-alpha-based combinations for treatment of sars-cov-2 and other viral infections 

      Ianevski, Aleksandr; Yao, Rouan; Zusinaite, Eva; Lello, Laura Sandra; Wang, Sainan; Jo, Eunji; Yang, Jaewon; Ravlo, Erlend; Wang, Wei; Lysvand, Hilde; Løseth, Kirsti; Oksenych, Valentyn; Tenson, Tanel; Windisch, Marc P.; Poranen, Minna M.; Nieminen, Anni I.; Nordbø, Svein Arne; Fenstad, Mona H.; Grødeland, Gunnveig; Aukrust, Pål; Trøseid, Marius; Kantele, Anu; Lastauskienė, Eglė; Vitkauskienė, Astra; Legrand, Nicolas; Merits, Andres; Bjørås, Magnar; Kainov, Denis (Journal article; Peer reviewed, 2021)
      Background: There is an urgent need for new antivirals with powerful therapeutic potential and tolerable side effects. Methods: Here, we tested the antiviral properties of interferons (IFNs), alone and with other drugs in ...